InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-02 | 2026-03-10 | Lyons Christopher Michael | Director | Purchase | 7,534 | $2.90 | $22K | 8,292 | View ↗ | |
| 2026-02-25 | 2026-03-10 | Lyons Christopher Michael | Director | Purchase | 758 | $2.96 | $2K | 758 | View ↗ | |
| 2026-02-23 | 2026-02-25 | MOYES JAY M | Director | Purchase | 1,000 | $2.91 | $3K | 4,000 | View ↗ | |
| 2026-02-18 | 2026-02-19 | Anderson Mark Lewis | Director | Purchase | 3,000 | $3.02 | $9K | 18.0K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Total revenue | $289K-82.4% | $1.6M+17.1% | $1.4M+45.9% | $960K |
| Cost of revenue | $557K-31.3% | $811K | — | — |
| Gross profit | $461K-77.8% | $2.1M+12.6% | $1.8M+42.2% | $1.3M |
| Research and development | $4.6M-11.8% | $5.2M-40.3% | $8.7M+35.1% | $6.5M |
| General and administrative | $6.2M+55.0% | $4.0M-5.3% | $4.2M+5.8% | $4.0M |
| Sales and marketing | $242K-60.6% | $614K-46.0% | $1.1M-14.9% | $1.3M |
| Armor exit costs | $4.6M | — | — | — |
| Reduction in force | $407K | — | — | — |
| Grant and contract expenses | $156K-88.0% | $1.3M+15.3% | $1.1M+32.0% | $855K |
| Total operating expenses | $11.2M-30.6% | $16.1M+6.1% | $15.2M+20.3% | $12.6M |
| Loss from operations | -$10.7M+23.7% | -$14.0M-5.2% | -$13.4M-17.8% | -$11.3M |
| Interest expense | -$52K-79.3% | -$29K-1350.0% | -$2K+88.2% | -$17K |
| Interest income | $175K+63.6% | $107K-20.7% | $135K+487.0% | $23K |
| Gain (loss) on the disposal of assets | $327K+1821.1% | -$19K-211.8% | $17K+1800.0% | -$1K |
| Change in fair value of derivative liabilities | -$124K-103.6% | $3.5M-39.2% | $5.7M+624.1% | -$1.1M |
| Offering costs of derivative liabilities | -$550K | — | -$786K | — |
| Other income (expense) | $31K-20.5% | $39K+129.4% | $17K-95.5% | $382K |
| Total other income (expense), net | $357K-88.2% | $3.0M-40.7% | $5.1M+824.3% | -$704K |
| Net loss before income taxes | -$10.4M+6.0% | -$11.0M-33.5% | -$8.3M+31.4% | -$12.0M |
| Net loss | -$10.4M+6.0% | -$11.0M-33.5% | -$8.3M+31.4% | -$12.0M |
| Deemed dividend related to warrant inducement | -$6.7M | — | — | — |
| Net loss attributable to common stockholders | -$17.1M-55.0% | -$11.0M-33.1% | -$8.3M+49.8% | -$16.5M |
| Basic – net loss | -$4K+74.8% | -$15K+96.6% | -$442K-1007.4% | -$40K |
| Basic – deemed dividend related to warrant inducement | -$2K | — | — | — |
| Basic – attributable to common stockholders | -$6K+58.6% | -$15K+96.6% | -$443K-711.2% | -$55K |
| Diluted – net loss | -$4K+75.4% | -$15K+97.6% | -$623K-1232.1% | -$47K |
| Diluted - deemed dividend related to warrant inducement | -$2K | — | — | — |
| Diluted – attributable to common stockholders | -$6K+59.4% | -$15K+97.6% | -$624K-926.9% | -$61K |
| Basic | $2.77B+274.2% | $741.3M+3867.7% | $18.7M-93.8% | $301.6M |
| Diluted | $2.77B+272.4% | $744.8M+3318.6% | $21.8M-93.1% | $317.3M |
| Product [Member] | ||||
| Total revenue | $289K-82.4% | $1.6M+17.1% | $1.4M+45.9% | $960K |
| Grant and Contract [Member] | ||||
| Total revenue | $289K-82.4% | $1.6M+17.1% | $1.4M+45.9% | $960K |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution
SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant
SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms
SINTX Technologies to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference on February 4–5